A Phase 1 Randomized, Double-masked, Vehicle-controlled, Dose Escalation Study of the Ocular Safety and Tolerability of MC-1101 in Medically Stable Individuals
Latest Information Update: 24 Apr 2014
Price :
$35 *
At a glance
- Drugs MC 1101 (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Sponsors MacuCLEAR
- 24 Apr 2014 New trial record